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Abstract
Background: Malaria is still a major health problem in some parts of the world. Plasmodium falciparum is the common
pathogenic parasite and is responsible for majority of malaria associated deaths. Recently the other benign parasite, P.
vivax, is reported to cause life threatening severe malaria complications. Thus, this study was aimed to assess incidence
of severe malaria symptoms caused by P. vivax parasite in some malaria endemic areas of Ethiopia.
Materials and methods: Presumptive malaria patients (all age groups) seeking medication at the selected health
facilities in Mendi town, Northwest Ethiopia, were recruited for the study. Socio-demographic, clinical and
parasitological characteristics were assessed following standard procedures. Data was analyzed using descriptive
statistics, chi-square test and relative risk.
Results: Of the 384 patients enrolled in the study for P. vivax mono-infection, 55 (14.3 %) of them were fulfilled at least
one of the WHO criteria for severe malaria indicators. Some of these clinical manifestations were: prostration 14 (25.
45 %), persistent vomiting 9 (16.36 %), respiratory distress 6 (10.9 %), hypoglycemia 5 (9.1 %), hyperpyrexia 8 (14.5 %),
and severe anemia 13 (23.63 %). Differences in parasite load did not affect the frequency of some severe malaria
symptoms. However, severe anemia, prostration, and persistent vomiting were significantly affected (P < 0.05) by
relatively higher load of parasitemia, (OR = 3.8, 95 % CI, 1.1–13.7; OR = 4.4, 95 % CI, 1.4–13.9; and OR = 7, 95 % CI, 1.8–27.
4) respectively.
Conclusion: P.vivax associated severe malaria symptoms observed in this study is supportive evidence for the notion
that P.vivax is no longer benign parasite but rather virulent. Thus, to meet international and regional targets of malaria
eradication, a holistic prevention and control approaches should be designed.
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Background
Malaria is one of the most important health problems in
developing countries. It is estimated that about half of
the world’s population are at risk of malaria [1, 2]. P. fal-
ciparum and P. vivax have worldwide distribution, with
P. falciparum being the more pathogenic. Few years
back, it was indicated that about 1–3 million mortality
per year, mainly in children and pregnant women, are
due to severe malaria caused by P. falciparum [3]. How-
ever, according to the latest report released by WHO [4]
there were an estimated 584,000 deaths globally. The
same report showing reduction of malaria mortality rates
among children in Africa by an estimation of 47 % glo-
bally since 2000 and by 54 % in the WHO African Re-
gion [4].
In Ethiopia malaria is unstable and seasonal. This is
because of the country’s heterogeneous topography and
climatic factors [5, 6]. Areas at altitudes between 1600
and 2000 m above sea level (masl) are epidemic-prone
hypo-endemic zones of malaria [7]. However, malaria
epidemics are expanding to areas as high as 2500 masl
[8]. On the other hand, although P. vivax is a rare para-
site in most parts of Africa, it is an important parasite in
Ethiopia. In some areas of the country the prevalence
rate even exceeds 70 % of total malaria infections. This
was previously reported due to the high Duffy positivity
trait of most population of Ethiopia, but recently contra-
dictory reports are coming [9–11]. In addition, chloro-
quine resistance pattern of P. vivax parasite is increasing
in the country [12]. Recently severe life threatening mal-
aria symptoms, frequently associated with P. falciparum,
has been reported from Asia, South America and Africa
for P. vivax [13–18]. Thus, the current study was aimed
to assess incidence of severe malaria symptoms due to P.
vivax infection in one of malaria endemic areas of
Ethiopia.
Methods
Description of the study area
A cross sectional study was conducted in Mendi Town,
located 567 km Northwest of Addis Ababa, the capital
city of Ethiopia (Fig. 1). Geographically the study site is
located at latitude and longitude of 9°48′N 35°6′E and
the mean altitude of 1538 masl. Annual rainfall ranged
from 900 to 1500 mm and main rainy season is from
May to October. The mean annual maximum
temperature of the area is about 32 °C (25–32). The two
principal parasites of malaria infection in the study area
are P. falciparum and P. vivax. The main vector in the
study area is A. arabiensis. Based on the 2007 Census
conducted by the Central Statistical Agency (CSA) of
Ethiopia, this town has a total population of 28,485 of
whom 14,385 are males and 14,100 females [19].
Study population
The study participants were all presumptive malaria pa-
tients seeking medication at the health center and clinic
in Mendi town, during the study period from September,
2014 to June, 2015 and those who had symptoms of
malaria infection. The inclusion criteria used were any
patient positive for P. vivax mono-infection (microscopy
confirmed), without any chronic illness, without prior
medication for the current illness, having clinical symp-
toms such as fever, chills, malaise, headache, vomiting,
Fig. 1 Map of the study site
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history of fever for about 48 h before admission, and vol-
unteer to participate in the study. Accordingly, a total of
384 patients who fulfilled the inclusion criteria were in-
cluded in the study.
Data collection
Clinical and demographic data were collected using pre-
designed case record form by trained health profes-
sionals working in the two health facilities. Clinical
symptoms such as fever, headache, diarrhea, hyperpy-
rexia, hemoglobunria, persistent vomiting, impaired con-
sciousness, convulsion, respiratory distress, persistent
vomiting, hypotension, anorexia, nausea, and rigor were
assessed following criteria set on guideline for malaria
diagnosis and treatment [20]. Body temperature of each
patient was measured using digital thermometer.
Patients with at least one symptom of severe malaria
complications set by World Health Organization
(WHO) were classified as severe P. vivax cases [20]. Pre-
liminary screening of the blood smears for P.vivax was
done by two experienced laboratory technician working
in the two health facilities. To ensure data quality, the
positive slides were further confirmed by certified senior
laboratory technician at Jimma University. Fortunately
there were no difference in their reading and the original
record was used for analysis. Detailed description of the
blood collection and smear preparation is as follows: a
drop of blood sample was collected on clean glass slide
from lancet pricked finger to prepare thin and thick
blood smears in duplicate per patient for microscopic
examination. Thick and thin blood smears were stained
with 3 % Giemsa (pH = 7.2, for 45 min), while thin
smears were fixed in methanol before Giemsa staining.
Malaria parasite was identified by observation of the
smears and the morphological appearance of the parasite
in the infected red blood cells (RBCs) using ×100 micro-
scope objective. Parasite load was calculated after count-
ing asexual parasites per 200 white blood cells (WBC),
assuming mean WBC count of 8000 count/μL using the
following formula:
Parasite load=μL ¼ Number of observed asexual parasites 8000 WBC count=μL
200 WBCs
The degree of parasitaemia was graded as mild, moder-
ate, and severe, when a count (x) is between 1 and 999
parasite/μL, 1000–9999/μL, >10,000/μL, respectively [21].
From the pricked finger, some drops of blood samples
were taken for quantification of levels of blood glucose
(Glu) (Senso Card Hungary) and hemoglobin (Hb) (Hemo-
cue™, haemoglobino meter, Angelholm, Sweden, Hb 301).
The patient was considered anemic when Hb level is <11 g/
dL (children) and <13 g/dL (adult male) and <12 g/dL dult
female). Further, level of anemia was classified as severe,
moderate and mild, when Hb level is <5 g/dL, between 5
and 8 g/dL, and between 8 and 11 g/dL, respectively [20].
Lower blood glucose (hypoglycemia) was considered when
blood glucose concentration was <40 mg/dL. Hyperpyrexia
was considered when body temp is ≥40 °C. All participants
were treated with Chloroquine sulfate as soon as the
blood sample was drawn and found positive for P.vivax
following National Guideline for Malaria Diagnosis and
Treatment [22].
Data analysis
Data was analyzed using SPSS statistical software (Ver-
sion 20.0. Armonk, NY: IBM Corp). Descriptive statistic
was used for analysis of some clinical, demographic and
parasitological data. Associations between variables were
computed using Pearson correlation. Responses were
compared using chi-square test, and relative risk was
used to assess strength of association between variables
in groups. In all analysis, significance level was consid-
ered at 95 % confidence interval (CI).
Results
Prevalence of malaria in the study area
The trend of malaria cases showed an irregular declining
pattern. However, the 5 years prevalence report (2010–
2014) of the two health facilities showed that, the num-
ber of malaria infected patients was still higher (Fig. 2).
Of the total 14, 844 individuals (8751 females and
6093 males) seeking medication at the two health facil-
ities, blood samples were collected from 4813 suspected
malaria cases. Accordingly, 1434 (818 males and 616 fe-
males) were found positive for malaria infection. Among
the positive cases, A total of 533 (37.2 %) and 851
(59.3 %) were infected with P. vivax and P. falciparum,
respectively, while, 50 (3.5 %) were due to mixed infec-
tion (P. vivax and P. falciparum). The highest peak in-
fection for P. falciparum and P. vivax was observed in
November followed by October (Fig. 3).
Socio-demographic and clinical characteristics of the
study participants
In the current study, a total of 384 patients that ful-
filled the inclusion criteria were clinically diagnosed
and enrolled in the study. Prevalence of malaria
among male and females patients were 52.6 % (n =
202) and 47.4 % (n = 182), respectively. Among differ-
ent age groups, the distribution of malaria infection
with respect to sex was almost similar, except in
those aged less than 5 years, where the infection was
higher among male population of the same age. In
terms of sex, male malaria patients (n = 202, 52.6 %)
were significantly higher than that of females (χ2 =
64.2, P < 0.05).
Median age of the study participants was 14 years (1
month to 60 years). Mean body temperature and blood
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glucose levels of the study participants were 37.89 °C
(35.5 to 40.8) and 104.4 mg/dL (36.8 to 180), respect-
ively. Also, the level of Hb and geometric mean para-
site counts were 12.4 g/dL (4.3–17.8) and
3745parasite/μL (280–31,600), respectively. The ob-
served anemic cases were 115 (29.9 %) (Table 1).
Status of uncomplicated malaria symptoms in P. vivax
mono-infected patients
Uncomplicated malaria symptoms observed in the
current study were headache 255 (66.4 %), aching 231
(60.2 %), chills 225 (58.6 %), vomiting 179 (46.6 %),
rigor 152 (39.6 %), shivering 151 (39.3 %), cramp
150 (39.1 %), nausea 147 (38.3 %), anorexia 61
(15.9 %) and diarrhea 22 (5.72 %) (Table 2). At the
time of admission, about 179 (46.6 %) and 22
(5.7 %) of the patients had vomiting, and diarrhea,
respectively. But, none had symptoms of splenomeg-
aly and hepatomegaly. Although most patients, 360
(93.8 %) had a history of fever for the past 48 h,
only 227 (59.1 %) were febrile or had axillary
temperature ≥37.5 °C (Table 2).
Fig. 2 Malaria cases among patients in Mendi town, Oromia, Northwest Ethiopia, 2010–2014
Fig. 3 Confirmed malaria cases during the study period at health facilities in Mendi town, Northwest Ethiopia, 2014/15
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Incidence of severe malaria symptoms
Severe malaria symptoms were observed in 55 (14.32 %)
patients infected with P. vivax mono-infection. A total
of 36 (65.5 %) patients fulfilled at least one of the WHO
criteria for severe malaria symptoms while 19 (34.5 %)
had two or more overlapping severity indicators. of the
later cases, 12 (63.2 %) had two combined symptoms, 5
(26.3 %) had three combined symptoms and the
remaining 2 (10.5 %) had four combined symptoms.
Some of these clinical manifestations were: prostration
n = 14 (25.45 %), persistent vomiting n = 9 (16.36 %), re-
spiratory distress n = 6 (10.9 %), hypoglycemia n = 5
(9.1 %), hyperpyrexia n = 8 (14.5 %) and severe anemia n
= 13 (23.63 %). Major severe malaria symptoms observed
were prostration, and severe anemia, in combination
with other symptoms including persistent vomiting, hy-
perpyrexia, and hypoglycemia. However, none had signs
of confusion, coma, hemoglobinuria or discoloration of
urine and hypotension (Table 3). None of the partici-
pants died during the study period.
Most severe malaria manifestations were presented in
children less than 5 years. To mention, severe anemia
was observed in 12 children aged less than 5 years and 2
children aged between 5 and 14, but none among adults.
These three severe symptoms were higher among chil-
dren under 5 years than other age groups (Table 4).
From the analysis made on association between para-
site load and severe malaria symptoms, it was observed
that differences in parasite load did not affect the occur-
rence of respiratory distress, hyperpyrexia, and
hypoglycemia. Significant differences were not observed
(P > 0.05) with respect to relative risk (RR) of P. vivax in-
fected patients of different parasite load (between 1000
and 9999, and ≥10,000). However, severe anemia, pros-
tration, and persistent vomiting were significantly associ-
ated (P < 0.05) with severe parasitemia (≥10,000 parasite/
μL), [(OR = 3.8, 95 % CI, 1.1–13.7; OR = 4.4, 95 % CI,
1.4–13.9; and OR = 7. 95 % CI, 1.8–27.4), respectively
(Table 5).
Discussion
The overall prevalence of malaria during the study
period (2014/15) was 29.8 %, (declined by 3.3 % from
the 33.1 % prevalence documented in 2005 by the two
local health facilities 2013) (Unpublished data). The
overall prevalence of malaria observed during the study
period was slightly lower than the recent report from
southern part of Ethiopia (31.9 %) [16] and much lower
than report from Nigeria (81.9 %) [23]. The possible
Table 1 Clinical and demographic characteristic of P. vivax
malaria infected patients, at Mendi town, Northwest Ethiopia
Clinical features Frequency
Age (years)
Median age 14 (1 month to 60 years)
• <5 101 (26.3 %)
• 5–14 97 (25.26 %)
• >14 186 (48.4 %)
Sex
• Male 202 (52.6 %)
• Female 182 (47.4 %)
Temperature 37.89 (°C)
Febrile cases 329 (85.7 %)
Blood glucose level 109.89 (mg/dL)
Hemoglobin level 12.4 (g/dL)
Anemic cases 115 (29.9 %)
Geometric mean parasite count 3745 (parasite/μL)
Table 2 Frequencies of uncomplicated symptoms in P. vivax
malaria infected patients, Mendi town, Northwest Ethiopia
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Table 3 Clinical manifestations of severe malaria symptoms in
patients (n = 55) infected with P. vivax, Mandi town, Northwest
Ethiopia
Clinical symptom Frequency (%)
Severe anemia 13 (23.63)
Respiratory distress 6 (10.9)
Prostration 14 (25.45)
Hyperpyrexia 8 (14.5)
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explanation for the observed discrepancy could be due
to the intense and diverse malaria control strategies
undertaken in most parts of the country [22].
P. vivax mono-infection has been associated with se-
vere and fatal disease in endemic areas [13, 24, 25]. The
observed severe malaria symptoms in this study (14.3 %)
was almost similar to reports from southern Ethiopia
(13.67 %) and Tertiary care center of central India
among hospitalized patients (17.2 %) due to P. vivax
malaria [16, 18], but lower than report from Eastern
Sudan’s New Halfa Hospital (27.8 %) [26]. The most
commonly encountered severe malaria manifestations of
P.vivax mono infection in this study were prostration,
followed by severe anemia, persistent vomiting, hyperpy-
rexia, respiratory distress, and hypoglycemia. As ob-
served in our study, severe malaria symptoms commonly
detected in P. vivax infected patients is severe anemia
[24]. This could be due to continuous presence of the
parasite in liver as hypnozoite stage, infecting and
destroying young RBCs [25]. Also, for every infected
RBC destroyed during P. vivax infection, 32 non-
infected RBCs are removed from the circulation, com-
pared to the loss of 8 RBCs for every infected erythro-
cyte in P. falciparum malaria [27]. Other assumption is
that anemia might occur as a result of rigor inflamma-
tory reactions [28] and phagocytosis of non-parasitized
red blood cells, increased splenic clearance, and dysery-
thropoiesis in bone marrow [29]. To this effect severe
anemia caused by P. vivax is responsible for 87 % of
severe diseases compared to 73 % of severe malaria com-
plications that occur due to P. falciparum [13]. In this
study, significant number of severe anemia patients was
children aged less than 5 years. The high susceptibility
of young children to severe anemia could be due to rela-
tively faster attainment of immunity to P. vivax than to
P. falciparum [30–32].
Frequency of respiratory distress due to P. vivax mono
infection observed in this study (10.9 %) was higher than
report from India (6.8 %) [18], but comparable with
other report from adults living in malaria-endemic areas
in Bikaner, Northwestern India (10 %) [14]. The possible
mechanism of pathogenesis of respiratory distress in P.
vivax malaria has been proposed to be severe alveolar
capillary dysfunction like in P. falciparum [33]. This is
evidenced by the comparable clinical manifestations of
acute respiratory distress syndromes (ARDS) in P. vivax
and P. falciparum infected patients [34–36].
Most of these symptoms are largely attributed to pro-
duction of various cytokines such as TNF- α produced
in response to the parasite and toxin products released
during rupture of infected RBCs [37]. Also, hemozoin
released from infected RBCs (iRBCs) leading to the re-
lease of pro-inflammatory cytokines that inturn induce
COX-2 (cyclooxygenase-2) up-regulating prostaglandins
leading to the induction of fever [38, 39]. As there is an
evidence for rigor inflammatory reactions due to pro-
inflammatory response and cytokines activation during
P. vivax infection [28], the hyperpyrexia and persistent
vomiting observed in this study could be due to the in-
tense inflammatory reaction caused by P. vivax.
Differences in parasite load did not affect the inci-
dence of severe malaria symptoms among assessed pa-
tients. This was in consistence with earlier report made
by Price et al. [40], which explained that P. vivax is cap-
able of inducing fever at levels of parasitemia lower than
those causing fever in P. falciparum infection [40].
WHO also reported that in western Thailand, a region
of low endemicity, the pyrogenic density for P. vivax was
180 parasites/μL compared to 1000 parasites/μL ob-
served in P. falciparum infection [41]. This is mainly be-
cause of the fact that P. vivax has a tendency to achieve
Table 4 Incidence of severe malaria symptoms among different
age groups of patients infected with P. vivax malaria, at Mandi
town, Northwest Ethiopia
Clinical features Age (year)
<5 5–14 >14
Respiratory distress 3 (57.9 %) 2 (31.6 %) 1 (10.5 %)
Hyperpyrexia 5 (62.5 %) 1 (12.5 %) 2 (25 %)
Persistent vomiting 5 (55.5 %) 3 (33.3 %) 1 (10 %)
Severe anemia 11 (84.6 %) 2 (15.4 %) 0 (0)
Prostration 8 (57.14 %) 4 (28.57 %) 2 (14.28 %)
Hypoglycemia 3 (60 %) 2 (40 %) 0 (0)
Table 5 Strength of association between parasitemia and severe malaria indicators in patients infected with P. vivax malaria, Mandi
town, Northwest Ethiopia, 2014/15
Parasite load Sever malaria indicators (%)
Severe anemia Respiratory distress Prostration Persistent vomiting Hyperpyrexia Hypoglycemia
Yes No Yes No Yes No Yes No Yes No Yes No
1000–9999 9 (3.4) 258 (96.6) 4 (1.5) 263 (98.5) 10 (3.7) 257 (96.3) 5 (1.9) 262 (98.1) 5 (1.9) 262 (98.1) 4 (1.5) 263 (98.5)
≥10,000 4 (11.8) 30 (88.2) 2 (5.9) 32 (94.1) 4 (12.1) 29 (85.3) 4 (11.8) 30 (88.2) 3 (8.57) 32 (94.1) 1 (2.9) 33 (97.1)
Relative risk (RR) RR = 0.26
(95 % CI, 0.076–0.9),
P = 0.034
RR =0.24
(95 % CI, 0.043–1.38),
P = 0.11
RR =0.28
(95 % CI, 0.08–0.95),
P = 0.042)
RR =0.14
(95 % CI, 0.036–0.56),
P = 0.005
RR =0.19
(95 % CI, 0.045–0.86),
P = 0.03
RR = 1.9
(95 % CI, 0.2–18.4),
P = 0.54
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and maintain lower density parasitemia as it only in-
vades young RBCs [42]. In addition, patients with P.
vivax infections also tend to present all parasite stages
that could be visible on the peripheral blood film [4, 43].
Hypothesis given for the lower parasitemia caused by P.
vivax may be due to the presence of the same parasite in
haemopoietic tissue than in the vascular sinus [35].
Thus, parasite load of P. vivax in peripheral blood could
expand rigorously without its detection [44].
Naturally, P. vivax causes an acute febrile illness with
no complications or death. However, recently reports on
complications due to P. vivax are globally increasing [29,
45, 46]. The exact causes of changes in the clinical pro-
file of P. vivax infection are uncertain. It is assumed
that, it may be due to genetic alterations of the parasite
or change in vector and its biting habits, indiscriminate
use of anti-malarial drugs, delayed treatment, or due to
declining efficacy of chloroquine or rise in chloroquine-
resistant P. vivax strains [47–49]. In addition, prolonged
existence of hypnozoite reservoir in patient’s liver could
cause recurrent infection even after patients successfully
treated [50]. The increasing evidence on severe malaria
complications associated with P. vivax has implication
on the current global target of malaria eradication. Using
knowledge and long experience accumulated over pe-
riods on P. falciparum, all concerned bodies including
policy makers, researchers and others working in the
same field should characterize clinical epidemiology and
economic burden of P. vivax in different geographical
areas for better management of burdens due to P.vivax
infection.
Study limitation
The lack of confirmation of absence of mixed infection
due to P.vivax and P.falciparium using PCR is a major
limitation of this study.
Conclusion
Some severe malaria complications such as prostration,
severe anemia, respiratory distress, hyperpyrexia and
persistent vomiting were observed in P. vivax mono-
infected individuals. This strengthens the fact that para-
site. P. vivax is no longer benign. Therefore, to meet the
set international targets for reduction of malarial mor-
bidity and mortality, and regional elimination of P.vivax
infection, concerned bodies should no longer neglect
this parasite.
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